Jose Medrano, MD
Obstetrics & Gynecology · Burbank, CANPI 1801880786
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,000 of the $10,989 with a category attached, or 63.7%. Mimedx Group, Inc. accounts for 63.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $4,168, 6.5 times the $637 reported in 2019. Among obstetrics & gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $52.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$7K
- AbbVie$1K
- Mayne Pharma Commercial LLC$321
- Therapeuticsmd, Inc.$279
- Astellas Pharma US Inc$255
- Evofem Biosciences, Inc.$251
- plus $2K from 24 others
Across 53 payments — averaging $3050.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$88K
- GSK$73K
- Duchesnay USA Incorporated$2K
What the payments were for
- Consulting fees$7,00064%
- Food & beverage$3,80235%
- Education$1872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 20 | $7,000 |
| AbbVie(2 entities) | 55 | $1,067 |
| Mayne Pharma Commercial LLC | 18 | $321 |
| Therapeuticsmd, Inc. | 10 | $279 |
| Astellas Pharma US Inc | 4 | $255 |
| Evofem Biosciences, Inc. | 23 | $251 |
| Hologic Sales And Service, LLC | 8 | $193 |
| Pfizer | 7 | $182 |
| Bayer | 8 | $154 |
| Exeltis, USA Inc. | 8 | $148 |
| Organon | 6 | $132 |
| Coopersurgical, Inc. | 7 | $110 |
| Myovant Sciences Inc. | 4 | $107 |
| Johnson & Johnson(2 entities) | 2 | $87 |
| Sage Therapeutics, LLC | 3 | $83 |
| Agile Therapeutics, Inc. | 4 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| Coloplast | 1 | $71 |
| Lupin Inc. | 5 | $71 |
| Baxter Healthcare | 2 | $61 |
| Merck | 3 | $58 |
| Vertex | 2 | $52 |
| Antares Pharma, Inc. | 1 | $24 |
| Smith+Nephew | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Mission Pharmacal Company | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Millicent US Inc | 1 | $18 |
| Scynexis, Inc. | 1 | $17 |
| Meditrina | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOVINE COLLAGEN$1,200
- Orilissa$111
How this compares
$10,989 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 18 | $8,520 |
| Estradiol | 30 | $1,478 |
| ValacyclovirValacyclovir Hcl | 11 | $561 |
| Metronidazole | 23 | $265 |
| Terconazole | 11 | $261 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $171 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $182 | $8,52018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Other obstetrics & gynecology in Burbank
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.